Bitsillin-5 powder prig.susp.v / m 1.2mln.ed 300tys.ed fl +

Description

Composition
Active substance:
1 vial contains: benzathine benzylpenicillin – 1,200,000 units, benzylpenicillin procaine salts (procaine benzylpenicillin) – 300000 IU.
Product form:
Powder for suspension for intramuscular 1200000 + 300000 ED ED. 1200000 + 300000 IU IU in 10 ml capacity vials. 1, 5 or 10 units with instructions for use placed in a pile of cardboard. 50 vials of 5 the instructions for use are placed in a box made of cardboard for delivery to hospitals.
Contraindications
Hypersensitivity to the drug, benzylpenicillin and other beta-lactam antibiotics. Lactation.
Dosage
1 200 300 thousand units
Indications
Infectious and inflammatory diseases caused by susceptible pathogens: continuous (all year round) relapse prevention of rheumatic fever; syphilis, yaws; Streptococcal infections (excluding infections caused by streptococcus group B) – acute tonsillitis, scarlet fever, wound infections, erysipelas.
pharmachologic effect
Pharmacological group:
The antibiotic penicillin biosynthetic.
Pharmacodynamics:
Combined bactericidal antibiotic, consisting of two long-acting salts of benzylpenicillin. It inhibits the synthesis of the cell wall of the microorganism. It is active against Gram-positive microorganisms: Staphylococcus spp. (Neobrazuyuschih penicillinase), Streptococcus spp. (Including Streptococcus pneumoniae), Corynebacterium diphtheriae, anaerobic spore-forming rods, Bacillus anthracis, Clostridium spp, Actinomyces israelii.; Gram-negative organisms: Neisseria gonorrhoeae, Neisseria meningitidis, Treponema spp.
By the action of the drug-resistant strains of Staphylococcus spp., Penicillinase.
Pharmacokinetics:
Bitsillin®-5 is a drug depot, a high concentration of antibiotic in blood stored for up to 4 weeks.
Benzathine benzylpenicillin.
After intramuscular injection of benzathine benzylpenicillin slowly hydrolyzed, releasing benzylpenicillin. The maximum concentration in serum drug achieved in 12-24 hours after injection. The long half-life and provides stable long term drug concentration in the blood: on day 14 after administration of 2400000 IU drug concentration in serum is 0.12 ug / ml; on the 21st day after the administration of the drug 1,200,000 IU – 0.06 ug / ml (1 IU = 0.6 g). Diffusion of the drug in a liquid full, diffusion in tissue is very weak. Communication with plasma proteins 40-60%. Benzathine benzylpenicillin extends in small quantities through the placental barrier and into breast milk mother. Biotransformation small drug. Excreted mainly by the kidneys in unchanged form. For 8 days is allocated to 33% of the administered dose.
Penicillin.
The maximum concentration in plasma after intramuscular administration is achieved after 20-30 min. The half-life of 30-60 min, renal failure 4-10 hours or more. Relationship to plasma proteins – 60%. Into the organs, tissues and body fluids, except CSF, eye tissue and prostate. When inflammation of the meningeal membranes penetrates the blood-brain barrier. It passes through the placenta and passes into breast milk. Excreted by the kidneys unchanged.
Pregnancy and breast-feeding
Bitsillin®-5 in small amounts crosses the placental barrier and into breast milk. Application of pregnancy is possible only when the intended benefits to the mother outweighs the potential risk to the fetus.
It is recommended to stop breast-feeding if necessary, the appointment.
Conditions of supply of pharmacies
On prescription.
Storage conditions
In a dry place at a temperature not higher than 20 C. Keep out of reach of children.
Dosing and Administration
Intramuscularly.
Adults – 1200000 U + 300000 IU 1 every 4 weeks.
Preschool children – 480,000 units 120,000 units + 1 every 3 weeks, for children older than 8 years – 960,000 units 240,000 units + 1 every 4 weeks.
For the preparation of suspensions using sterile water for injection, isotonic sodium chloride solution or a 0.25-0.5% solution of procaine (novocaine).
A suspension of 5-Bitsillina® aseptically prepared, immediately before use (ex tempore): the vial under pressure slowly (at a rate of 5 ml for 20-25 seconds) is administered 5-6 mL of solvent. Stirred contents of the vial and the vial is shaken along its longitudinal axis to form a homogeneous slurry. Presence of bubbles on the surface of the slurry in the vial walls. The suspension Bitsillina®-5 immediately after preparation is administered by deep intramuscular injection in the upper outer quadrant of the gluteal muscle. Rubbing the gluteal muscles after injection it is not recommended. By introducing a delay immediately after the preparation of modified physical and colloidal properties of the suspension, causing its motion may be hindered by the syringe needle.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist